Immix Biopharma, Inc. Quarterly Revenues in USD for Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Immix Biopharma, Inc. quarterly Revenues history and growth rate for Q4 2022.
  • Immix Biopharma, Inc. Revenues for the quarter ending December 8, 2022 was $20M.
Revenues, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $20M Dec 8, 2022 10-Q 2024-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.